AbbVie Inc. $ABBV Stock Sold by Greenup Street Wealth Management LLC

Greenup Street Wealth Management LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 44.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,217 shares of the company’s stock after selling 1,763 shares during the period. Greenup Street Wealth Management LLC’s holdings in AbbVie were worth $580,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Ranch Capital Advisors Inc. lifted its stake in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK boosted its position in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in AbbVie in the second quarter valued at about $23,557,000. Wedge Capital Management L L P NC grew its stake in AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after purchasing an additional 9,380 shares during the last quarter. Finally, State Street Corp grew its stake in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. Scotiabank boosted their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Wells Fargo & Company raised their price target on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. Rothschild & Co Redburn lifted their price objective on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Trading Up 1.4%

Shares of ABBV opened at $294.80 on Friday. The firm has a market cap of $520.85 billion, a PE ratio of 83.28, a P/E/G ratio of 1.33 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The stock has a fifty day moving average price of $269.35 and a 200-day moving average price of $237.23.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the previous year, the business earned $1.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts forecast that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.